| Literature DB >> 31258517 |
Geetanjali Ganguli1, Utsav Mukherjee1, Avinash Sonawane1,2.
Abstract
Host redox dependent physiological responses play crucial roles in the determination of mycobacterial infection process. Mtb explores oxygen rich lung microenvironments to initiate infection process, however, later on the bacilli adapt to oxygen depleted conditions and become non-replicative and unresponsive toward anti-TB drugs to enter in the latency stage. Mtb is equipped with various sensory mechanisms and a battery of pro- and anti-oxidant enzymes to protect themselves from the host oxidative stress mechanisms. After host cell invasion, mycobacteria induces the expression of NADPH oxidase 2 (NOX2) to generate superoxide radicals ( O 2 - ), which are then converted to more toxic hydrogen peroxide (H2O2) by superoxide dismutase (SOD) and subsequently reduced to water by catalase. However, the metabolic cascades and their key regulators associated with cellular redox homeostasis are poorly understood. Phagocytosed mycobacteria en route through different subcellular organelles, where the local environment generated during infection determines the outcome of disease. For a long time, mitochondria were considered as the key player in the redox regulation, however, accumulating evidences report vital role for peroxisomes in the maintenance of cellular redox equilibrium in eukaryotic cells. Deletion of peroxisome-associated peroxin genes impaired detoxification of reactive oxygen species and peroxisome turnover post-infection, thereby leading to altered synthesis of transcription factors, various cell-signaling cascades in favor of the bacilli. This review focuses on how mycobacteria would utilize host peroxisomes to alter redox balance and metabolic regulatory mechanisms to support infection process. Here, we discuss implications of peroxisome biogenesis in the modulation of host responses against mycobacterial infection.Entities:
Keywords: macrophages; mitochondria; mycobacteria; oxidative stress; peroxisomes
Year: 2019 PMID: 31258517 PMCID: PMC6587667 DOI: 10.3389/fmicb.2019.01121
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1Host pathogen interaction: pathogenic Mtb enters the host via interaction between different host surface receptors like Toll like receptors (TLRs), mannose receptors (MRs), scavenger receptors (SRs), complement receptors (CRs) and so on and cognate Mtb ligands. These interactions modulates the phagosome maturation, downstream signaling molecules (like MYD88, IRAK-4, etc.), signaling pathways (like MAPK, autophagy, apoptosis, etc.) and transcription factors (like PPARG and NFκB) to favor bacillary persistence and reduced antigen presentation inside host cells.
List of PPAR agonists/ligands and its related diseases.
| PPAR ligands | Related diseases | Mode of action | References | ||
|---|---|---|---|---|---|
| PPARA | Agonist | Eupatilin | Degeneration of gastric mucosa | Cryoprotective effects against gastric mucosal damage by inducing anti-inflammatory and anti-oxidative phenotype | |
| Atopic dermatitis | Downregulates the expression of TNFA. IFNG and IL1B | ||||
| Resveratrol | Obesity and metabolic syndrome | Increase in MUFA and PUFA | |||
| Fibrates | Hypertriglyceridemia Hypoalphalipoproteinemia | Downregulates hepatic apolipoprotein C-III thereby stimulating lipoprotein lipase gene | |||
| Antagonist | NXT629 | Chronic lymphocytic leukemia (CLL) | Inhibits PPARA agonists induced transcription of PPAR- α on CLL cells thereby inhibiting drug resistance and immunosuppressive property in the host | ||
| PPARB/D | Agonists | GW501516 GW0742 L-165041 | Obesity Type-2 diabetes Dyslipidemia Non-alcoholic fatty liver disease | Decreases subcutaneous and visceral adipose tissues Recovers glucose tolerance and insulin sensitivity Elevates lipid catabolism Introduces and equilibrium between pro- and anti-inflammatory molecules thereby reducing liver damage and inflammation | |
| Antagonist | GSK0660 GSK3787 | Psoriasis | Induces anti-inflammatory property upon topical application | ||
| FH535 | Cancer | Introduces anti-proliferative activity in the cancer cells via inhibition of Wnt/β-catenin signaling pathway | |||
| PPARG | Agonist | Prostaglandins | Cystic fibrosis Cancer Alzheimer’s disease and Parkinson’s disease | Inhibits the expression of | |
| Induces neuronal cell survival and neuro-protection | |||||
| Thiazolidinediones (TZDs) | Type-2 diabetes Dyslipidemia Parkinson’s disease | Induces insulin sensitizing properties Balances extra- and intra-cellular lipid metabolism Profound expression of PPARG due to agonists lead to suppression of microglial activity thereby preventing neurodegeneration | |||
| Fibrates | Dyslipidemia | Balances extra- and intra-cellular lipid metabolism | |||
| Unsaturated FA | High cholesterol Cardiovascular disease Hypertension | Alters membrane lipid concerto, cellular metabolism, and signal transduction | |||
| Antagonist | GW9662 T0070907 | Hematopoietic cancer | Induces anti-proliferative activity and apoptosis | ||
FIGURE 2(A) Oxidative stress response. Following entry of Mtb into host cells results in the generation of oxidative stress responses. Mtb employs several strategies to combat these stress mechanisms, which includes activation of anti-oxidant enzymes (like superoxide dismutase, catalase/peroxidase, etc.), redox-sensors (like DosR regulon system) and redox buffering system. Phagocytosis of Mtb leads to formation of superoxide radical via NADPH oxidase. As evasion strategy, Mtb genes reduce the superoxide radical into less toxic intermediates using anti-oxidant enzymes. The pathway eventually inhibits the process of autophagy, apoptosis and cellular damage. (B) Mycobacterial oxidative stress response gene family protein, WhiB, combats the redox and nitrosative stress via the Fe–S clusters while DosS and T gene from DosR regulon senses the redox imbalance and activates the DosR to furtheractivate the dormancy pathway.
List of known Mycobacterium tuberculosis oxidative stress response genes.
| Gene name | Function | References |
|---|---|---|
| Reduces superoxide radicals to peroxide | ||
| Reduces peroxide radicals to molecular oxygen and water | ||
| Thiosulfate oxidation activity | ||
| Senses oxidative stress, combats hypoxic condition and dormancy | ||
| Thiosulfate oxidation activity | ||
| Defense against reactive oxygen and nitrogen intermediates by reducing peroxide radicals to molecular oxygen and water | ||
| Peroxide detoxification | ||
| Offer defense against oxidative stress via NADH-dependent peroxidase and peroxynitrite reductase | ||
| Peroxide detoxification | ||
| Inhibition of oxidative stress and autophagy pathway via MAPK pathway | ||
| Higher intracellular survival by causing ROS dependant genomic instability | ||
| Succinate dehydrogenases complexes | Modulates oxidative phosphorylation and central metabolism by maintaining membrane potential for energy production | |
| Help in maintaining redox homeostasis and latency reactivation | ||
| Transcriptional regulator of Katg gene | ||
| Modulates cellular metabolism | ||
| Modulates fatty acid synthase thereby regulating oxidative metabolism | ||
| Reactive nitrogen intermediate resistance gene inhibits the nitrostative stress inside the infected macrophages | ||
| Modulates redox homeostasis and lipid metabolism | ||
| Nucleotide-binding universal stress protein alters metabolic pathways via arginine in an ATP-dependent manner | ||
| Oxidation-sensing regulator, upregulates the expression of several oxidoreductases | ||
| Stress-induced extracytoplasmic sigma factor, transcriptionally regulates the expression of different anti-oxidants | ||
| Modulates acidic pH, hypoxia inside infected macrophages | ||
| Oxidative stress regulators works in combination with aph and fur genes | ||
| Manipulates the expression of both antioxidant genes and enzymes involved in the process of DNA repair which results in resistance toward oxidative stress and anti-bacterial activity of macrophage |
FIGURE 3Crosstalk between mitochondria and peroxisome: the pathogenic Mtb enters into the macrophage cells via different PRRs like mannose receptor (MRs) or TLRs. After phagocytosis, Mtb modulates cellular oxidative stress mechanisms. Inside the mitochondria, NOX2 generates the superoxide radicals during the ETC cycle. These superoxide radicals are then metabolized to hydrogen peroxide by superoxide dismutase. Anti-oxidant enzyme catalase eventually breaks down the toxic H2O2 into water and molecular oxygen. This phenomenan helps to increase the bacillary count inside the cells. In peroxisomes, the bacteria metabolize the stored fatty acids and lipids for its survival. During the peroxisomal β- fatty acid oxidation, acyl CoA oxidases, and other peroxisomal oxidases metabolizes the very long chain fatty acids (VLCFA) into short chain fatty acids (SCHFA) and acetylCoA. The SCHFA is exported into the mitochondria for further metabolism to generate ATP. The acetyl CoA is used as an intermediate molecule in the glyoxylate shunt pathway. In addition to generation of SCHFA, cellular ROS is formed which is further catalyzed by the array of anti-oxidant enzymes in peroxisomes like catalase, glutathione peroxidise (GPX), and so on. This phenomenon further provides a favorable niche for the bacilli to survive.
FIGURE 4De novo biogenesis of peroxisomes: peroxisomes originate from endoplasmic reticulum (ER) and mitochondria. With the help of different peroxins like PEX3, 16, 19, and also peroxisomal membrane proteins (PMPs) active organelle is formed. Balance in cellular oxidative metabolism results in balanced redox interplay between pro- and anti-oxidants of peroxisomes thereby helping in the proper growth and division of daughter peroxisomes from pre-existing peroxisomes via the expression of PEX11, DLP-1, Fis, and Mff.
FIGURE 5A representation for Pexophagy: PEX5 is stabilized by the mono-ubiquitination at K464 position via TRIM37, which further helps in maintaining the peroxisome homeostasis. In response to peroxisomal ROS, PEX5 undergoes polyubiquitination via activation of ATM-kinase. PEX5 is degraded via proteosome lysis thereby inducing Pexophagy via activation of autophagy adaptor molecules SQSTM1/p62 and NBR1. Degradation of PEX5, leads to peroxisomal disintegration and removal of PEX3 and other peroxins. Removal of PEX3 initiates peroxisome sequestration via activation of PEX14, which acts as a docking site for LC3II. The interaction eventually leads to degradation of bulky and damaged organelles via Pexophagy.